AAV8-3m vector system (Pancreas-validated AAV expression and packaging plasmid system) (Amp and Kanamycin) (GeneMedi Owned)
GeneMedi (GM) AAV8 variant (Y733F, Y447F, Y275) Vector system is including: 1) AAV8 variant (Y733F, Y447F, Y275) Rep-Cap plasmid (AAV8 variant (Y733F, Y447F, Y275)-RC plasmid) 2) AAV Helper plasmid 3) AAV expression vectors (overexpression or shRNA).
You can produce AAV8 variant (Y733F, Y447F, Y275) particle in 293T cell line in high titer using GeneMedi's AAV8 variant (Y733F, Y447F, Y275) Rep-Cap plasmid with GM's AAV expression vector (overexpression or shRNA) and AAV helper plasmid.
The tissue tropism of AAV8-3m vector has been validated in in Pancreas, Pancreatic Tumors and retina,with potential applications in tissue-specific gene therapy and cancer therapy.
GeneMedi offers both Ampicillin (Amp) resistance and Kanamycin (Kan) resistance for the AAV Rep-Cap Plasmids, AAV expression Plasmids and AAV helper Plasmid.
Product Description
Cat.NO | Product Name | Organization Type | Price(In USD) | ||
---|---|---|---|---|---|
P-PK12 | AAV8 variant(Y733F,Y447F, Y275) Vector System (Amp resistance) 1. AAV8 variant (Y733F, Y447F, Y275) Rep-Cap Plasmid, 5ug 2. AAV Helper Plasmid, 5ug 3. pGMAAV-CMV-MCS-T2A-ZsGreen (P-AAVV-B01), 5ug | Academic | 3024 | ||
P-PK12 | AAV8 variant(Y733F,Y447F, Y275) Vector System (Amp resistance) 1. AAV8 variant (Y733F, Y447F, Y275) Rep-Cap Plasmid, 5ug 2. AAV Helper Plasmid, 5ug 3. pGMAAV-CMV-MCS-T2A-ZsGreen (P-AAVV-B01), 5ug | Biotech & Pharma & Medical Device & Diagnostics | |||
P-PK12 | AAV8 variant(Y733F,Y447F, Y275) Vector System (Amp resistance) 1. AAV8 variant (Y733F, Y447F, Y275) Rep-Cap Plasmid, 5ug 2. AAV Helper Plasmid, 5ug 3. pGMAAV-CMV-MCS-T2A-ZsGreen (P-AAVV-B01), 5ug | CRO&CDMO& CXO&CMC& Manufacturing company |
|||
P-PK12 | AAV8 variant(Y733F,Y447F, Y275) Vector System (Amp resistance) 1. AAV8 variant (Y733F, Y447F, Y275) Rep-Cap Plasmid, ≥10mg 2. AAV Helper Plasmid, ≥10mg 3. pGMAAV-CMV-MCS-T2A-ZsGreen (P-AAVV-B01-Kan), ≥10mg |
All | |||
P-PK12-Kan | AAV8 variant(Y733F,Y447F, Y275) Vector System (Kan resistance) 1. AAV8 variant (Y733F, Y447F, Y275) Rep-Cap Plasmid (Kan resistance) , ≥10mg 2. AAV Helper Plasmid (Kan resistance) , ≥10mg 3. pGMAAV-CMV-MCS-T2A-ZsGreen (Kan resistance) (P-AAVV-B01-Kan), ≥10mg |
All | |||
P-RC12 | AAV8 variant(Y733F,Y447F, Y275) Rep-Cap
Plasmid (Amp resistance)
Size:5ug |
Academic | 1719 | ||
P-RC12 | AAV8 variant(Y733F,Y447F, Y275) Rep-Cap
Plasmid (Amp resistance)
Size:5ug | Biotech & Pharma & Medical Device & Diagnostics | |||
P-RC12 | AAV8 variant(Y733F,Y447F, Y275) Rep-Cap
Plasmid (Amp resistance)
Size:5ug | CRO&CDMO& CXO&CMC& Manufacturing company |
|||
P-RC12 | AAV8 variant(Y733F,Y447F, Y275) Rep-Cap
Plasmid (Amp resistance)
Size:≥10mg |
All | |||
P-RC12-Kan | AAV8 variant(Y733F,Y447F, Y275) Rep-Cap
Plasmid(Kan resistance)
Size:≥10mg |
All | |||
GeneMedi offers both seed and amplification services for the Amp-resistant AAV Vector System. GeneMedi only offers amplification services and do not provide seed for the Kan-resistant AAV Vector System currently. |
|||||
If you want to obtain higher quantities of plasmids (mg), please visit GM TransExcellent Plasmid DNA Rapid Preparation Service. | |||||
Terms of sale: For Seed (5ug): The purchaser may not reverse engineer this product to extract the sequence for independent use. The purchaser may not transfer this product to others for manufacturing purposes. The purchaser may not use this material to manufacture this product for any other party. For plasmid production& amplification (≥10mg): The purchaser may not reverse engineer this product to extract the sequence for independent use. The purchaser may not transfer this product to others for manufacturing purposes. The purchaser may not use this material to manufacture this product for themselves or any other party. |
Citation
Title | Publication | Date |
---|---|---|
A novel polypeptide encoded by the circular RNA ZKSCAN1 suppresses HCC via degradation of mTOR | Molecular Cancer | 2023/1/23 |
Lipid-accumulated reactive astrocytes promote disease progression in epilepsy | Nature Neuroscience | 2023/3/20 |
Apoptosis-resistant megakaryocytes produce large and hyperreactive platelets in response to radiation injury | Military Medical Research | 2023/12/19 |
Lysosomal-associated protein transmembrane 5 ameliorates non-alcoholic steatohepatitis by promoting the degradation of CDC42 in mice | Nature Communications | 2023/5/8 |
Pulmonary Surfactant Homeostasis Dysfunction Mediates Multiwalled Carbon Nanotubes Induced Lung Fibrosis via Elevating Surface Tension | ACS nano | 2023/12/15 |
Photoreceptor protection by mesenchymal stem cell transplantation identifies exosomal MiR-21 as a therapeutic for retinal degeneration | Cell Death & Differentiation | 2020/10/6 |
Multi-region sequencing unveils novel actionable targets and spatial heterogeneity in esophageal squamous cell carcinoma | Nat Commun | 2019/4/11 |
SUMO1 regulates post-infarct cardiac repair based on cellular heterogeneity | Journal of Pharmaceutical Analysis | 2022/12/5 |
FABP4 secreted by M1-polarized macrophages promotes synovitis and angiogenesis to exacerbate rheumatoid arthritis | Bone Research | 2022/7/22 |
LncIRS1 controls muscle atrophy via sponging miR-15 family to activate IGF1-PI3K/AKT pathway | J Cachexia Sarcopenia Muscle | 2019/1/30 |
Validation data
No data found
Associated products and services
Products & Service | Products & Service Information |
---|---|
AAV Packaging service | Detail |
Promise-ORF™ viral CDNA library | Detail |
Plasmid DNA Rapid Preparation Service | Detail |